Evoke Pharma, Inc. (EVOK)
NASDAQ: EVOK · Real-Time Price · USD
5.25
-0.04 (-0.76%)
At close: Sep 5, 2025, 4:00 PM
5.21
-0.04 (-0.76%)
After-hours: Sep 5, 2025, 5:55 PM EDT
Evoke Pharma Revenue
Evoke Pharma had revenue of $3.75M in the quarter ending June 30, 2025, with 47.06% growth. This brings the company's revenue in the last twelve months to $12.79M, up 70.02% year-over-year. In the year 2024, Evoke Pharma had annual revenue of $10.25M with 97.84% growth.
Revenue (ttm)
$12.79M
Revenue Growth
+70.02%
P/S Ratio
1.08
Revenue / Employee
$4,264,953
Employees
3
Market Cap
10.87M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 10.25M | 5.07M | 97.84% |
Dec 31, 2023 | 5.18M | 2.67M | 106.51% |
Dec 31, 2022 | 2.51M | 890.57K | 55.04% |
Dec 31, 2021 | 1.62M | 1.60M | 6,929.00% |
Dec 31, 2020 | 23.02K | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
EVOK News
- 11 days ago - MAI Capital Management Announces Strategic Partnership with Evoke Advisors - Business Wire
- 12 days ago - Evoke Pharma and EVERSANA Expand GIMOTI® Access to Gastro Health and Other Large GI Practices through Omnicell Relationship - GlobeNewsWire
- 17 days ago - Evoke Pharma Announces Listing of New GIMOTI® Patent in FDA Orange Book - GlobeNewsWire
- 4 weeks ago - Evoke Pharma Announces Issuance of New U.S. Patent for GIMOTI With Extended Exclusivity to Late 2038 - GlobeNewsWire
- 2 months ago - Evoke Pharma Receives Notice of Allowance for U.S. Patent Application for GIMOTI Extending Orange Book listings to 2036 - GlobeNewsWire
- 4 months ago - Evoke Pharma Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - Evoke Pharma to Present New Data Comparing Tardive Dyskinesia Incidence in Continuous vs Intermittent Metoclopramide Use at DDW 2025 - GlobeNewsWire
- 6 months ago - Evoke Pharma, Inc. (EVOK) Q4 2024 Earnings Call Transcript - Seeking Alpha